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Background: The serological diagnosis of celiac disease (CD) often relies on the presence of anti-tissue transglutaminase
(tTG) IgA autoantibodies. Patients suffering from selective IgA deficiency (IgAD) are often not aware of their IgA
deficiency and are tested as CD negative, delaying considerably the diagnosis. The detection of IgG against
deamidated gliadin peptides (DGP) has high specificity and better sensitivity than IgG anti-tTG. A multi-analytic
lateral-flow immunochromatographic assay (CD-LFIA) based on the detection of IgA and IgG anti-DGP and total
IgA was shown to have a good diagnostic accuracy for CD. The aim of this study was to evaluate the clinical
accuracy of its use in children suffering from IgAD.
Methods: 45 IgAD children ranging from 1.1 to 17.4 years and suspected of CD or having high CD risk factors
were referred from outpatient clinics located in the area of Rhone-Alpes (France) to the Hospices Civils de Lyon,
Paediatric Hospital-Gastroenterology-Hepatology- Nutrition Department for further CD investigations. The CD
investigations, including the sample collection, were performed within the Paediatric Hospital-Gastroenterology-
Hepatology- Nutrition Department, and the serological testing was performed at the Lyon-Sud Hospital-Immunology
Laboratory. The diagnosis of CD was based on IgG anti-tTG serology, biopsy results and patient follow-up. The serum
samples were retrospectively tested on the CD-LFIA test.
Results: A total of eight (8) patients were diagnosed as new CD. All were correctly identified by the CD-LFIA.
The test yielded four (4) false positive results. Two patients with positive IgG anti-tTG were negative on CD-LFIA,
but were classified as CD negative based on biopsy results and patient follow-up. The remaining 33 patients were
found negative by both methods. The specificity and sensitivity of CD-LFIA was of 89.2% [74.6-97.0] and of 100%
[63.1-100] respectively. The negative predictive value (NPV) was of 100% [89.4-100], and the Likelihood Ratio for
Negative Test (LR-) was of 0 [0.0-0.91].
Conclusions: CD-LFIA is a useful, non-invasive and rapid tool to rule out CD in primary care paediatric patients
having CD-related symptoms and IgAD. Patients having a positive CD-LFIA result could be then readily directed
to secondary care setting for further evaluation by standard serology and biopsy.
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Selective IgA deficiency (IgAD) is a common immuno-
deficiency occurring in Caucasians with a prevalence
rising up to 1:600 [1,2]. IgAD is characterized by total IgA
serum levels below 0.06 g/L and normal levels of IgM
and IgG [3]. Although the majority of IgAD individuals
are asymptomatic, IgAD is associated with autoimmune* Correspondence: silvia.anghel@augurix.com
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unless otherwise stated.disorders such as celiac disease (CD) [4]. Its frequency
is raised and estimated to be about 1:40 among patients
suffering from CD [5-7].
The European Society for Paediatric Gastroenterology
Hepatology and Nutrition (ESPGHAN) strongly recom-
mends testing for the presence of IgA autoantibodies
against tissue transglutaminase (tTG) as the initial step for
CD diagnosis [5,8,9]. Moreover, in cases where the total
IgA status is unknown, the guidelines strongly recom-
mend IgA measurement [8-10]. In case of IgAD, a positiveal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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midated gliadin peptides (DGP) antibodies is considered
as diagnostically relevant [8-10].
Unfortunately, investigation of the total IgA levels is
frequently neglected, and patients suffering from IgAD
are often not aware of their IgA deficiency and may
therefore be tested as CD negative, delaying considerably
the diagnosis [3,11]. Recently, it has been demonstrated
that the detection of IgG against DGP has a high specifi-
city and a better sensitivity than IgG anti-tTG [12-16].
Therefore, their use was suggested as an alternative for
the diagnosis of CD in IgAD patients [3].
A multi-analytic lateral-flow immunochromatographic
assay (CD-LFIA) based on the rapid detection of both
IgA and IgG anti-DGP and total IgA has previously been
shown to have a good diagnostic accuracy to rule out
CD in high-risk paediatric and adult populations [17,18].
The aim of the present study was to evaluate its use as
a tool to rule out CD in children suffering from IgAD.
Methods
Patients
Paediatric patients suspected of CD or having high CD
risk factors were referred from outpatient clinics located
in the area of Rhone-Alpes (France) to the Hospices
Civils de Lyon, Paediatric Hospital-Gastroenterology-
Hepatology- Nutrition Department for further CD inves-
tigations. The CD investigations, including the sample
collection, were performed within the Paediatric Hospital-
Gastroenterology-Hepatology- Nutrition Department, and
the serological testing was performed at the Lyon-Sud
Hospital-Immunology Laboratory. From 2001 to 2012, 45
paediatric patients were selectively diagnosed with IgAD
with total IgA levels below 0.06 g/L. The study stems
from collaboration between the Paediatric Hospital-
Gastroenterology-Hepatology- Nutrition Department and
the Lyon-Sud Hospital-Immunology Laboratory. Ethical
approval was obtained from the Ethical Committee of
Hospices Civils de Lyon for the retrospective use of
the samples collected within the Paediatric Hospital-
Gastroenterology-Hepatology- Nutrition Department
and analyzed within the Lyon-Sud Hospital-Immunology
Laboratory. The samples were anonymized, and informa-
tion was collected on the CD related symptoms and/or
high risk factors, on the serological investigation, biopsy
results, and finally on the patient follow-up when avail-
able. From the 45 IgAD paediatric patients, 17 were tested
because of clinical suspicion of CD (diarrhea, anemia,
and failure to thrive), 18 because of risk factors for CD
(autoimmune diseases among which 14 suffer from type
1 diabetes), and finally ten (10) patients were not clinically
documented. To our knowledge, none of the patients
included in this study were diagnosed with another
small intestinal disorder at the time of CD diagnosis.Diagnostic methods
Total IgA was measured using the BNII nephelometer
(Siemens) according to the manufacturer’s protocol. IgAD
was diagnosed when total IgA levels were below 0.06 g/L.
For the study population, normal values ranged between
0.12 g/L and 2.03 g/L, depending on the patient’s age.
The CD diagnosis was made by the gastroenterologist,
and was based on results of serologic enzyme-linked im-
munosorbent assay (ELISA) IgG anti-tTG test (see below),
small intestine mucosal biopsy examination and on patient
follow-up when available.
IgG anti-tTG levels were measured by the ELISA test
Celikey® from Thermo Fisher (Uppsala, Sweden). Concen-
trations >5 U/mL were considered as positive.
In case of discrepancy between IgG anti-tTG and CD-
LFIA, IgG anti-DGP levels were measured by the ELISA
test Varelisa® Gliadin Antibodies from Thermo Fisher
(Uppsala, Sweden). Concentrations >10 U/mL were con-
sidered as positive.
At endoscopy, 4–6 duodenal biopsies were taken from
patients having a positive IgG anti-tTG serology [8]. The
duodenal biopsies were analyzed by an experienced histo-
pathologist, who assessed the following pathologic features
of CD: villous atrophy, crypt hyperplasia, increased intrae-
pithelial lymphocytes, and chronic inflammation in the
lamina propria. The diagnosis of CD was subsequently
confirmed according to the modified Oberhuber-Marsh
classification [19].CD-LFIA test
The serum samples were tested by CD-LFIA test
(Simtomax® Augurix, Switzerland) according to the manu-
facturer’s instructions. The CD-LFIA point-of-care device
detects simultaneously both human IgA and IgG anti-
DGP, as well as total IgA in 10 to 15 minutes [17,18].
Briefly, the test was read as CD positive and IgAD when
both the control line and the line corresponding to anti-
DGP detection could be seen. Each sample was tested on
one device by two independent user-operators blinded to
the subject’s history and laboratory findings. Prior to the
clinical study, each user-operator had completed a one-
day course on the use of CD-LFIA.Statistical analysis
The laboratory ELISA IgG anti-tTG, biopsy results, and
patient follow-up were used as “standard diagnosis” for
comparative analyses to evaluate the testing features of
CD-LFIA.
The CD-LFIA test’s sensitivity, specificity, diagnostic
accuracy, and positive and negative likelihood ratios
(LR+, LR-) and their corresponding 95% confidence
intervals (CIs) were calculated using the STATA soft-
ware (version 11; College Station, TX, USA).
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Patient’s characteristics
The diagnostic performance of CD-LFIA was retrospect-
ively tested on serum samples from 45 paediatric patients
diagnosed as IgAD, and initially tested by ELISA and
biopsy (when requested) because of clinical suspicion of
CD or risk factors for CD. Ten (10) patients were not clin-
ically documented.
The age of the population ranged from 1.1 to 17.4 years,
with a mean and median age of 8.2 and 8.4 years,
respectively, with 40% of females (n = 18), and 60% of
males (n = 27). 50% of females were initially investigated
because of CD-related symptoms, whereas 28% of them
were at high-risk of CD (diagnosed with autoimmune dis-
eases). In contrast, the majority of the male population
was suffering from autoimmune disease (48%, with a clear
overrepresentation of type 1 diabetes, n = 11), whereas
30% were suffering initially from CD-related symptoms
(Table 1).
Overall agreement between CD-LFIA and the “standard
diagnosis”
Based on the “standard diagnosis” (IgG anti-tTG positive
serology, biopsy result and patient follow-up), eight (8)
new cases of CD were found, all were correctly identified
by CD-LFIA (Figure 1). Their histology revealed subtotal
(n = 1; Marsh 3b) or complete villous atrophy (n = 7;
Marsh 3c).
From these eight cases, five (5) were among females
and were all initially tested because of CD related symp-
toms, particularly diarrhea, whereas among the three (3)
newly identified celiac positive male patients, one had
CD related symptoms, and two (2) were suffering from
type 1 diabetes. The age of the newly diagnosed CD
ranged from 1.5 to 17.4 years.
Thirty-seven patients were diagnosed as celiac negative.
Among them, 33 were correctly identified by CD-LFIA.
Four (4) patients were identified as positive on CD-LFIA.
The IgG anti-DGP levels of these four (4) patients were
further measured by ELISA and among them, two (2) had
positive levels of IgG anti-DGP. One of these patients
underwent duodenal biopsy one year later, and the result
showed a negative histology, and was therefore considered
as CD negative. The second patient (2.1 years old),
showed IgG anti-tTG levels near the cut-off (3.4 U/ml
instead of 5 U/ml) and positive levels of IgG anti-DGP





Population having risk factor
(Autoimmune disease)
Females 18 9 5
Males 27 8 13and no biopsy was conducted. Both patients were further
considered as false positive (Figure 1).
Among the celiac negative patients, two (2) patients
were weakly positive on the ELISA IgG anti-tTG (5 and
9.9 U/ml) and negative on CD-LFIA and ELISA IgG
anti-DGP. Based on their medical follow-up and their
normal biopsies they were considered as CD negative.
Thus, no false negative results were detected using CD-
LFIA (Figure 1).
Diagnosis in patients suffering from other autoimmune
disease
Among the 45 paediatric patients, 18 were suffering of other
autoimmune diseases, among which 15 were suffering of
type 1 diabetes. Fourteen (14) of them had concordant
results between ELISA IgG anti-tTG, ELISA IgG anti-DGP
and CD-LFIA.
Among the four remaining patients, two patients (6 and
15.6 years males) had positive ELISA IgG anti-tTG results
(5 and 9.9 U/ml) but were diagnosed as CD negative based
on their biopsy and follow-up. Both patients had negative
CD-LFIA and ELISA IgG anti-DGP results. A 5.6 years
old male suffering from type 1 diabetes was found nega-
tive on both ELISA IgG anti-tTG and anti-DGP but was
positive on CD-LFIA. Finally, an 11.2 years old female
diagnosed as CD negative based on ELISA IgG anti-tTG
result had a negative CD-LFIA result and a positive ELISA
IgG anti-DGP result (43 U/ml). Unfortunately, no biopsy
and further follow-up was conducted.
Evaluation of the diagnostic performance of CD-LFIA
These results yield a sensitivity for CD-LFIA device of
100% [63.1-100], and a specificity of 89.2% [74.6-97.0]
(Figure 2). The Negative Predictive Value (NPV), which
takes into account false negative results, was of 100%
[89.4-100] and the Likelihood Ratio for Negative Test
(LR-) was of 0 [0.0-0.91] (Figure 2). The overall diagnostic
accuracy was of 91.1% [78.8-97.5].
Discussion
The diagnosis of CD is a challenge for many physicians.
Unfortunately, up to 75% of CD remains undiagnosed,
and the time between the onset of symptoms and diagno-
sis is often too long [20,21]. It is thought that the use of a
highly sensitive rapid point- of- care test, performed in
primary care centers, may help physicians to rule out CD








4 1.3 to 17.4 8.4 8.8
6 1.1 to 16.2 8.1 7.3
Figure 1 Histogram comparing standard diagnosis by IgG anti-tTG ELISA assay and/or biopsy and/or follow-up to CD-LFIA test results.
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ter and more reactive patient support, decreasing the time
to diagnosis while increasing the patient quality of life.
According to the last ESPGHAN guidelines, the initial
testing of patients suspected of CD should be the sero-
logical identification of IgA autoantibodies against tTG,
followed by biopsy in case of a positive serology [8]. In
case of serology/biopsy disagreement, measurement of
total IgA levels and IgG anti-tTG or anti-DGP as well as
HLA-DQ genotyping are recommended. However, based
on epidemiological studies, it is known that IgAD occurs
with a higher frequency in CD positive patients [2,4-7].
Regardless the fact that ESPGHAN recommends the
measurement of total IgA levels [8] their determinationFigure 2 Diagnostic performance of CD-LFIA [with 95% CI].is often neglected, which obviously delays even more the
time to diagnosis of CD in patients suffering from IgA
deficiency. Therefore, there is a clear need for reliable
and easy to perform tests in primary care centers, that
could detect CD regardless of the total IgA status of
patient.
As mentioned above, the initial standard serological
test is based on IgA anti-tTG antibodies. In case of
IgAD, one can think of using IgG anti-tTG or anti-EMA
antibodies. However, several clinical studies showed that
IgG anti-tTG antibodies are not as sensitive and specific
as the IgA anti-tTG antibodies, and the use of EMA
assay in daily practice is limited by high costs and sub-
jective interpretations [25]. In contrast, several studies
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specificity and a better sensitivity than IgG anti-tTG
[12-16,26] and this seems to be also true in case of IgA
deficiency [3,27,28].
A multi-analytic lateral-flow immunochromatographic
assay (CD-LFIA) based on the rapid detection of both
IgA and IgG anti-DGP and total IgA was previously
shown to have a good diagnostic accuracy to rule out
CD in high-risk paediatric and adult populations [17,18].
Since the test detects IgA and IgG antibodies against DGP
and total IgA levels and it has a very good sensitivity and
NPV value, it seems to us that the test could facilitate the
management of paediatric patients, including undiagnosed
IgAD, consulting in primary care centers for CD-related
symptoms. Therefore, the aim of the present study was to
evaluate its use as a tool to rule out CD in children suffer-
ing from IgAD.
Within the 45 paediatric IgAD patients included in the
study, eight (8) were newly identified CDs, all of them
were correctly identified by CD-LFIA. From the remaining
37 patients, which were considered as CD negative, 33
were correctly identified by CD-LFIA and four (4) were
considered as false positive. Among them, one patient
underwent duodenal biopsy and was subsequently diag-
nosed CD negative. A second patient (2.1 years old) had
positive levels of IgG anti-DGP by ELISA. Although the
recent ESPGHAN guidelines recommend the use of
antibodies against DGP in children younger than 2, and
several papers showed that antibodies against DGP out-
perform EMA and tTG antibodies in children under
2 years of age, the patient had no further follow-up and
no endoscopic examination [8,9,13,28,29]. From the 33
CD negative patients, two (2) had a positive IgG anti-
tTG serology but were diagnosed as CD negative based
on their biopsy results and follow-up. Both patients
were correctly diagnosed by CD-LFIA, and therefore
CD-LFIA did not yield false negative results.
Limitations that apply to our study are foremost its
retrospective nature in a high pretest population. The
decision of conducting the study retrospectively in a
secondary care setting was principally guided by the
low prevalence of IgAD that could eventually increase
the length of the study. Clinical symptoms were missing
for ten (10) of the 45 patients included in this study.
However, diagnostic agreement was found between the
serologic IgA anti-tTG and CD-LFIA for all these patients,
all being CD negatives.
Conclusion
With a sensitivity of 100% [63.1-100], a NPV of 100%
[89.4-100] and a LR- of 0 [0.0-0.91], we showed here
that CD-LFIA is a useful, non-invasive and rapid tool to
rule out CD in primary care paediatric patients having
CD-related symptoms and IgAD. By detecting in a singletest, both IgA/IgG anti-DGP and total IgA, CD-LFIA
appears to be well adapted to the recommendations
concerning the systematic investigation of IgA levels in
patients screened for CD [8-10]. Patients having a positive
CD-LFIA result could be then readily directed to second-
ary care setting for further evaluation by standard serology
and biopsy.
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